Tactile Systems (TCMD) Stock Forecast & Price Target

Tactile Systems Tech is favored because its core lymphedema franchise is expanding in a large, under-penetrated market, with 3Q26 lymphedema sales up about 13% year over year and double-digit growth for the 5th consecutive quarter. Revenue of $91.9 million in 3Q26 topped expectations, adjusted EPS of $0.31 exceeded estimates, and gross margins improved by roughly 150 basis points, showing strong execution and better operating leverage. Management also raised adjusted EBITDA expectations to $50 million-$52 million while new product and channel catalysts, including Flexitouch Pro, MyoSleeve, and a stabilizing Airway Clearance business, support further growth and improving profitability.

Tactile Systems Tech is facing a negative setup because FY26 guidance was trimmed to $360M-$366M as Airway Clearance revenue fell 25.1% Y/Y to $10.0M, with management attributing the weakness to elevated DME inventory tied to the next-generation AffloVest launch. Although Lymphedema is expected to grow, the business remains exposed to slower-than-expected commercial uptake, competition in Airway Clearance, and uneven doctor support for pneumatic compression, limiting the durability of growth. The outlook is further pressured by G&A running 200 bps above consensus, gross margins easing to about 76%-76.5%, and adj. EBITDA only around $49M-$52M despite 9%-11% Y/Y revenue growth.